A universal vaccine to protect against all types of influenza A and B
Official title: Universal Influenza A/B Vaccine
Funded at Orlance, INC. · NIH-10846562 · Data updated 2026-11-12
This study is working on a new flu vaccine that could protect against different types of the virus by using a special method to deliver the vaccine directly to your skin, and it's currently being tested in animals before it can be tried in people.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Orlance, INC. NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | August 7, 2020 |
| Project end | April 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $1,000,000 |
| NIH project number | 5R44AI153011-04 |
| Project ID | NIH-10846562 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research would include individuals at high risk for influenza, such as the elderly, young children, and those with compromised immune systems.
✕Less likely to help
Patients who are not at risk for influenza or those who have already been vaccinated with existing influenza vaccines may not receive significant benefit from this research.
What this research studies
This research focuses on developing a universal influenza vaccine that targets conserved antigens of influenza viruses to generate strong immune responses. The approach involves using DNA vaccination delivered through an innovative Gene Gun device, which enhances the immune response by effectively targeting skin cells and antigen-presenting cells. The project aims to create a comprehensive vaccine that provides protection against both influenza A and B types, with initial testing conducted in animal models before advancing to human trials.
Why it matters
Potential benefit: If successful, this research could lead to a vaccine that provides broad protection against all strains of influenza A and B, potentially reducing the incidence of flu-related illnesses.
How similar studies have gone: Other research has shown promise in developing universal influenza vaccines, but this specific approach using DNA vaccination and the Gene Gun device is relatively novel.
Where this research is happening
-
Orlance, INC.
Seattle, United States Active
Researchers
- Principal investigator: Bagley, Kenneth C — Orlance, INC.
- Study coordinator: Bagley, Kenneth C
Related research
Other NIH-funded projects on the same topics.
-
Creating vaccines for influenza and other infectious diseases
This study is all about creating new vaccines to help protect people from the flu and other infections, so patients can look forward to better options for staying healthy.
-
Creating vaccines for human trials against influenza and other infectious diseases
This study is working on creating new vaccines to help protect people from flu and other infectious diseases, including those that could be used in harmful situations, so that everyone can have safer and more effective options to stay healthy.
-
Understanding flu and COVID-19 vaccine responses in people and in the lab
Researchers at Stanford explore how flu and COVID-19 vaccines work in people and in lab tests to improve protection for adults.
-
Surveillance and preparedness for flu and other respiratory pathogens in Kenya
A US-based research grant aims to improve how Kenya detects and prepares for influenza and other respiratory diseases to protect people there and global health.
-
Enhanced Seasonal Influenza Vaccine Targeting Shared and Variable Viral Antigens
A new DNA-based influenza vaccine approach aims to provide both precise protection against circulating strains and broader defense against unexpected strains.
-
How the immune system responds to flu shots and flu infection
This project looks at how adults' immune systems react after flu shots or when they catch the flu to find why some people get better protection than others.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.